Second generation S1P pathway modulators: research strategies and clinical developments.

@article{Bigaud2014SecondGS,
  title={Second generation S1P pathway modulators: research strategies and clinical developments.},
  author={Marc Bigaud and Danilo Guerini and Andreas Billich and Fr{\'e}d{\'e}ric Bassilana and Volker Brinkmann},
  journal={Biochimica et biophysica acta},
  year={2014},
  volume={1841 5},
  pages={
          745-58
        }
}
Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system (CNS) through demyelination and neurodegeneration. Until recently, major therapeutic treatments have relied on agents requiring injection delivery. In September 2010, fingolimod/FTY720 (Gilenya, Novartis) was approved as the first oral treatment for relapsing forms of MS. Fingolimod causes down-modulation of S1P1 receptors on lymphocytes which prevents the invasion of autoaggressive T cells into the… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain

  • The Journal of experimental medicine
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Characterization and Prediction of Cardiovascular Effects of Fingolimod and Siponimod Using a Systems Pharmacology Modeling Approach.

  • The Journal of pharmacology and experimental therapeutics
  • 2017
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED